--- title: "Oncotelic Therapeutics 2025 10-K: Net income $249.02M; EPS $0.59" type: "News" locale: "en" url: "https://longbridge.com/en/news/282896898.md" description: "Oncotelic Therapeutics reported a net income of $249.02 million for 2025, primarily due to a fair value gain on its GMP Bio investment. The company had a loss from operations of $3.19 million, an improvement from the previous year. Net income before taxes was $360.57 million, largely from a $365.35 million fair value change. The joint venture with GMP Bio advanced OT-101 development and is pursuing a Hong Kong IPO. The company also expanded its nanoparticle platform and integrated AI for biomarker discovery." datetime: "2026-04-15T20:35:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282896898.md) - [en](https://longbridge.com/en/news/282896898.md) - [zh-HK](https://longbridge.com/zh-HK/news/282896898.md) --- # Oncotelic Therapeutics 2025 10-K: Net income $249.02M; EPS $0.59 Oncotelic Therapeutics reported a net income of $249.02 million for the year ended December 31, 2025, driven primarily by a fair value gain on its investment in GMP Bio; diluted and basic earnings per share were $0.59. The company recorded a loss from operations of $3.19 million for 2025, an improvement versus the prior year. Net income before taxes reflected a $360.57 million figure attributable largely to a $365.35 million fair value change in the GMP Bio investment. **Financial Highlights** - **Operating Income**: $(3.19) million loss from operations for year ended Dec 31, 2025 (improved $0.39M vs 2024). - **Net Income (Loss) before income taxes**: $360.57 million, reflecting a $365.35 million change in fair value of the investment in GMP Bio. - **Net Income**: $249.02 million for year ended Dec 31, 2025 (compared with $(4.78) million in 2024), driven by fair value gain. - **Net income attributable to Oncotelic Therapeutics**: $249.28 million after adjustments for non-controlling interest. - **Net Income Per Share**: $0.59 basic and diluted for year ended Dec 31, 2025. **Business Highlights** - **Joint Venture Progress**: GMP Bio joint venture advanced OT-101 development, completed a Phase 1 OT-101 plus IL-2 trial and initiated studies in pancreatic cancer, non-small cell lung cancer, and mesothelioma. - **Valuation & Strategic Plans**: The joint venture obtained an independent pipeline valuation of $2.3 billion and is pursuing a Hong Kong IPO alongside third-party financing to scale operations. - **Nanoparticle Platform & Manufacturing**: The Nano/Deciparticle platform expanded to support multiple oncology candidates and the GMP San Diego facility is licensed for drug manufacturing. - **AI & Automation Integration**: The PDAOAI matured into a TGF-β knowledge platform for biomarker discovery and the company partnered with TechForce to commercialize GMP robotics. Original SEC Filing: Oncotelic Therapeutics, Inc. \[ OTLC \] - 10-K - Apr. 15, 2026 **Disclaimer** This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC. ### Related Stocks - [GTBP.US](https://longbridge.com/en/quote/GTBP.US.md) - [GBIO.US](https://longbridge.com/en/quote/GBIO.US.md) - [ONCY.US](https://longbridge.com/en/quote/ONCY.US.md) - [MBIO.US](https://longbridge.com/en/quote/MBIO.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [IHI.US](https://longbridge.com/en/quote/IHI.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) ## Related News & Research - [MindBio Therapeutics Corp. (CSE: MBIO) Harnesses Key AI, Voice Analysis to Offer Impairment Solution](https://longbridge.com/en/news/286418745.md) - [](https://longbridge.com/en/news/286807703.md) - [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md) - [MindBio Therapeutics Corp. (CSE: MBIO) Leveraging AI, Voice Analysis to Develop Intoxication Detection](https://longbridge.com/en/news/286102416.md) - [Incyte expands Genesis Molecular AI collaboration, pays USD 120 million upfront](https://longbridge.com/en/news/287060301.md)